By Dani Kass · July 9, 2020, 6:58 PM EDT
Already a subscriber? Click here to login
American Axle & Manufacturing v. Neapco Holdings LLC
Appellate - Federal Circuit
830 Patent Infringement (Fed. Qst.)
April 04, 2018
Dana-Farber Cancer Institute v. Ono Pharmaceutical Co., Ltd.
Appellate - Federal Circuit
830 Patent Infringement (Fed. Question)
June 19, 2019
Hologic, Inc. v. Minerva Surgical, Inc.
Appellate - Federal Circuit
830 Patent Infringement (Fed. Qst.)
June 21, 2019
Appellate - Federal Circuit
830 Patent Infringement (Fed. Qst.)
October 24, 2019
California, et al., Petitioners v. Texas, et al.
Supreme Court
2890 Other Statutory Actions
January 03, 2020
Texas, et al., Petitioners v. California, et al.
Supreme Court
2890 Other Statutory Actions
February 14, 2020
TCL Communication Technology Holdings Limited, et al., Petitioners v. Telefonaktiebolaget LM Ericsson, et al.
Supreme Court
830 Patent Infringement (Fed. Question)
May 06, 2020
The Chamberlain Group, Inc., Petitioner v. Techtronic Industries Co., et al.
Supreme Court
830 Patent Infringement (Fed. Question)
May 19, 2020
United States, Petitioner, v. Arthrex, Inc., et al.
Supreme Court
-
June 29, 2020
Smith & Nephew, Inc., et al., Petitioners v. Arthrex, Inc., et al.
Supreme Court
-
July 02, 2020
Arthrex, Inc., Petitioner v. Smith & Nephew, Inc., et al.
Supreme Court
-
July 06, 2020
November 06, 2024
How The Patent System May Look After Trump's ReturnOctober 17, 2024
Justices Urged To Fix 'Novel Misreading' Of IP Safe HarborOctober 07, 2024
Fed. Circ. Questions If Safer OxyContin Profits Came From IPSeptember 27, 2024
Kappos' Bayh-Dole Warning To Clients Draws DebateSeptember 24, 2024
Novo Nordisk Tells Sens. Ozempic Costs Are Linked To PBMsAugust 13, 2024
Entresto Release Delayed As Novartis Goes To Fed. Circ.August 06, 2024
Fed. Circ. Told Edwards Filed Safe Harbor Suit With Bad IntentJuly 10, 2024
Drug Pricing, Overreach Dominate IP Disclaimer FeedbackMay 28, 2024
Edwards Urges Full Fed. Circ. To Limit FDA Safe HarborApril 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor